The purpose of this study was to evaluate the influence of intracranial hypertension in the cerebrospinal fluid (CSF) levels of amphotericin B and fluconazole levels of patients with cryptococcal meningitis. CSF samples and intracranial pressure were obtained by means of routine punctures performed at days 1, 7, and 14 of therapy, respectively. Amphotericin B and fluconazole CSF levels were measured by HPLC method as previously described. The minimum inhibitory concentration for amphotericin B, fluconazole, 5´flucytosine, and voriconazole of each Cryptococcus isolate was performed according to CLSI. The predominant Cryptococcus species found was C. neoformans, and the major underlying condition was AIDS. Only one CSF sample had a detectable level for amphotericin B during the 14 days of therapy. Fluconazole CSF levels progressively increased from day 1 to day 14 of therapy for most cases. Fluconazole levels in the CSF were above the minimum inhibitory concentrations (MICs) for Cryptococcus during the initial 14 days of antifungal therapy. Variations of intracranial pressure did not affect amphotericin B and fluconazole levels in the CSF. The generalized estimating correlation (GEE) and Spearman correlation test (SCT) showed no significant correlation between the amphotericin B or fluconazole concentrations in the CSF and intracranial pressure (P = .953 and P = .093, respectively for GEE test and P = .477 and P = .847, respectively, for SCT). Combination therapy of amphotericin B with fluconazole was effective in 60% of the patients considering CSF cultures were negative in 9 of 15 patients after 14 days of therapy. Further studies are
Introduction
Cryptococcal meningitis can cause significant morbidity and mortality in the immunocompromised host and invasion of the central nervous system (CNS), which may lead to devastating consequences. 1 More than 50% of the patients with cryptococcal meningitis exhibit intracranial hypertension. [1] [2] [3] [4] [5] Approximately 600,000 deaths associated with cryptococcal meningitis occur annually worldwide. 6 Intracranial hypertension is responsible for both early mortality and cognitive sequelae of cryptococcal meningitis. 3, 4, 7 Risk factors for cryptococcal infection include human immunodeficiency virus (HIV), liver cirrhosis, diabetes mellitus, malignancies, and corticosteroids use. However, the disease may also occur in immunocompetent hosts who are without any apparent underlying disease. 8 The treatment of CNS infections is often difficult because the blood-brain barrier limits diffusion of drugs into the CNS and tissue efflux pumps can reduce CNS drug concentrations. In experimental fungal infections of the brain, with the probable exception of cryptococcal meningitis, outcome correlates with brain parenchymal antifungal penetration and antifungal CSF concentrations accumulation. 9 Infectious Diseases Society of America recommends measuring the CSF pressure in patients with cryptococcal meningitis using a manometer for lumbar puncture at initial and follow-up assessment. Intracranial hypertension requires the removal of CSF using lumbar puncture and can even require shunts in refractory cases. The current recommended therapy for cryptococcal meningitis in HIVinfected patients consists of at least 2 weeks of amphotericin B (AmB) in combination with 5´flucytosine (5-FC) followed by fluconazole for a minimum of 8 weeks. 10 However, during this follow-up study, 5-FC was currently not available in some areas of Brazil, while fluconazole (FCZ) is widely available, even in a generic formulation or through a donation program.
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Data regarding the relationship between the pharmacokinetics of FCZ and AmB in the CSF in patients with cryptococcal meningitis and intracranial hypertension is not available in the literature. Considering that intracranial hypertension might affect the penetration and concentration of antifungal agents in the central nervous system, the current recommended dosage for these drugs in this setting would have to be modified. Thus, the purpose of this study was to investigate the relationship between intracranial hypertension and the CSF concentration of AmB and FCZ in patients with cryptococcal meningitis.
Methods

Patients and clinical samples
A follow-up study was performed during January 2015 to December 2015 at Hospital de Clínicas de Porto Alegre, a tertiary-care hospital in southern Brazil. Patients admitted with meningitis due to Cryptococcus sp. were included in the study. Cryptococcal meningitis cases were diagnosed by direct examination and cerebrospinal fluid sample culture. Except for two patients treated with lipid complex and lipossomal amphotericin B (5.0 mg/kg daily) and fluconazole (800 mg daily), all patients were initially treated with amphotericin B deoxycholate (1.0 mg/kg daily) and fluconazole (800 mg daily) intravenously for 14 days. The study was approved by the local ethics committee. An informed consent was signed by the patients or their caregivers. The charts of the patients were consulted during the follow-up period to collect clinical data including age, sex, underlying disease, opening intracranial pressure, microbiology data, and clinical outcome. The CSF samples were collected by lumbar puncture at least 3 times according to the institutional protocol: on the day of diagnosis (D1), on day 7 (D7), and 14 (D14) after diagnosis. During the CSF collection, the opening intracranial pressure was measured with a manometer and the value of each pressure measured was registered on the chart of each patient. Repeated therapeutic lumbar punctures were performed if opening pressures >250 mm H 2 O. Cytology and manual white blood cells (WBCs) count in the CSF were performed using a hemocytometer for all collected samples. We could not obtain CSF samples and the opening intracranial opening pressure in some patients. D1 was used as the blank sample for AmB and FCZ. C. neoformans and C. gattii isolated from the CSF were identified based on the phenotypic method Lcanavanine glycine bromothymol Blue Medium test at the Microbiology Unit as previously described. 12 Minimum inhibitory concentration for AmB, FCZ, voriconazole (VRZ), and 5-FC, were assessed according to CLSI guideline M27-A3. 13 AmB (∼80%, HPLC powder) and FCZ (≥98% purity) were purchased from Sigma-Aldrich.
Chromatographic Standardization for CSF levels of AmB and FCZ
A stock solution of 1 mg/ml of each antifungal agent was prepared. The AmB powder was dissolved into DMSO and the FCZ powder was dissolved in distilled water. For the AmB calibration curve, the AmB and FCZ were diluted in a pool of CSF from persons without AmB or FCZ treatment to calibrator levels of 0; 0.1; 0.25; 0.5 and 1.0 μg/mL for AmB and 0; 2.5; 5.0; 10; 25 and 50 μg/ml for FCZ. For quality control, we produced some dilutions of AmB and FCZ (0.1 and 0.5 for AmB and 2.5 and 10 for FCZ) in known concentrations and analyzed these controls 3 times: before starting the measurements, during the measurements, and in the end of the samples measurement. The protein precipitation was performed using acetonitrile. We used 250 μl of the CSF sample and added 250 μl of acetonitrile. The mixture was vortexed for 30 seconds and centrifuged at 11,000 g for 10 minutes. The supernatant was transferred to a new cup and a volume of 50 μl of the clear extract was injected into the chromatographic system for each one of the analysis. The accuracy and precision of the analytical method were evaluated using quality control samples injected into the HPLC for intra-day precision evaluation. The same procedure was performed for consecutive days to determine the inter-day precision and accuracy. The concentration of each sample was determined using the calibration curve prepared and analyzed on the same batch. Chromatographic analysis of AmB was performed using UV-VIS detector in an LC-10A liquid chromatograph (Shimadzu, Kyoto, Japan). The separation was done with a Supelco BDS Hypersil C18 (150 × 4.6 × 5 μm) column and the mobile phase was constituted by acetic acid (0,73%) and acetonitrile (60:40 v/v), pH = 4.5 at room temperature, the wavelength was 407 nm, flow rate at 0.6 ml/min and retention time was 3 minutes. 14 The lowest quantifiable limit for AmB was 0.1 μg/ml. Chromatographic analysis of FCZ was performed using UV-VIS detector in an LC-10A liquid chromatograph (Shimadzu, Kyoto, Japan). The separation was done with a Supelco BDS Hypersil C18 (150 × 4.6 × 5 μm) column and the mobile phase was constituted by acetonitrile and water (30:70 v/v), at room temperature, with a wavelength of 210 nm, flow rate of 0.7 ml/min and retention time of 3.7 minutes 15 . The lowest quantifiable limit for FCZ was 2.5 μg/ml.
Statistical analysis
The database was organized using an Excel spreadsheet (Microsoft Office Excel 2007); after that, all of the data collected were analyzed using the SPSS (version 18.0.0) software, and the statistical test used was the Spearman correlation to correlate the IP and FCZ concentrations in the CSF. Applied generalized estimating equation (GEE) was used to verify the behavior of the intracranial pressure and FCZ concentrations in the CSF during the follow-up period proposed for this study for each patient. In addition, a descriptive analysis was performed.
Results Table 1 contains the details of the 15 patients included in the study. Most of the patients were male (70%). Among them, two patients (13.3%) had C. gattii, and 13 patients (86.7%) had C. neoformans isolated from the CSF. The most common underlying condition was AIDS (66.6%), followed by solid organ transplant (26.6%). Four patients (26.7%) died, and 11 patients survived (73,3%) after 10 weeks of follow-up. All 15 patients (100%) used AmB and FCZ for the treatment of cryptococcal meningitis. Considering 5-FC was not available in our institution during the study, no patient used this antifungal agent. Levels of AmB and FCZ in the CSF from the patients with cryptococcal meningitis are shown in Table 2 (supplementary table) . Nine (60%) of 15 patients presented negative fungal cultures after 14 days of antifungal therapy. Only three of 15 patients (20%) presented detectable but low levels of AmB in the CSF during the initial 14 days of antifungal therapy. All detectable AmB concentrations were 0.1 μg/ml (the lowest quantifiable limit). FCZ CSF levels progressively increased from day 1 to day 14 of therapy for most cases. In contrast to AmB levels, FCZ levels were normally above the MIC for Cryptococcus. As shown in Figure 1 and Figure 2 , variations of the intracranial pressure from normal to high levels did not influence the CSF concentrations of AmB and FCZ. The generalized estimating correlation (GEE) and Spearman correlation test (SCT) showed no significant correlation between the AmB or FLU concentrations in the CSF and intracranial pressure (P = .953 and P = .093, respectively for GEE test and P = .477 and P = .847, respectively for SCT).
Discussion
Intracranial hypertension is a common neurologic complication in critically ill patients and is also the common pathway in the presentation of many neurologic and nonneurologic disorders. 16 Intracranial hypertension is reported in HIV and non-HIV patients with cryptococcal meningitis. 2, 17 Graybill et al. studied a large series of patients (221 patients) with cryptococcal meningitis reported that more than 50% of these patients had opening pressures > 250 mm H 2 O on the initial lumbar puncture 4 . As described by other authors, intracranial hypertension may occur due to several factors in cryptococcal meningitis including the cryptococcal strain causing infection, particular conformation and capacity of a given patient´s CSF absorption pathways, and the viscosity of the CSF. 2 Intracranial hypertension impairs CSF passage, and develop microscopic plugs of polysaccharide that blocks the CSF flow. 18 A large number of yeast cells are often present in the CSF and meninges in autopsy sections, and this type of cell is substantially larger than the red cells of blood so that the yeast cells may block the channels and valves of the subarachnoid villi. Current guidelines for management of cryptococcal disease do not address the role of intracranial pressure on the pharmacokinetics of antifungal agents and possible dose modifications in patients with cryptococcal meningitis and intracranial hypertension. 10 In experimental studies, if the CSF outflow resistance increases, moderate reduction of the CSF production and absorption rates can be seen. 19 In the context of brain delivery, the increased intracranial pressure may present an obstacle to efficient drug delivery. The event of drug delivery against an interstitial pressure gradient has been substantially studied in solid tumors biology. Experimental in vivo studies have documented that interstitial pressure is raised in most solid tumors and this issue represents the major difficulty to the transfer of chemotherapeutics from the blood into the tumor. 20, 21 It is also possible that similar issues may be important in the delivery of drugs into the damaged brain. In a cat model of focal cerebral ischemia, Hatashita and Hoff measured the interstitial cerebral pressure and hydraulic tissue resistance in edematous tissue. 22 The authors found that edemainduced interstitial pressures may represent an impasse to the efficient delivery of drugs via the intraventricular route and similar constraints may also be applied for intraventricular delivery. Therefore, cerebral edema and intracranial hypertension could affect drug delivery, especially to damaged brain in stroke and trauma. 23 AmB is a large lipophilic molecule so that its size impedes the entry of the drug into the CNS. Its size impedes the entry of the drug into the CNS, which results in low, subtherapeutic levels in the CNS. 9 Some studies found that CSF concentrations of unencapsulated AmB were below 4% of the corresponding serum or plasma levels. 9, 24 Consequently, a systemic application of standard doses results in low, frequently subtherapeutic levels in the CNS compartments, but an increase of the daily dose is limited by its toxicity. According to our results, AmB levels in the CSF were below the MICs for cryptococcus, which was not influenced by wide variations of intracranial pressure. Even though, and despite of intracranial hypertension in most cases, combination therapy with AmB and FCZ without the association of 5-flucytosine was effective, considering most of the patients had negative CSF cultures at 14th day of therapy. FCZ readily penetrates into the CNS and achieves elevated concentrations in the CSF, even in models with an intact blood-brain barrier, the concentrations were in the range of 42-84% of those observed in serum. 25 FCZ was administered to all patients in our study. The FCZ levels found in the CSF were above the MIC for Cryptococcus isolates at the seventh day of antifungal therapy. Variations of intracranial pressure in patients with cryptococcal meningitis did not influence FCZ levels in the CSF concentrations independent of the inflammatory response expressed by the number of leukocytes in the CSF (Table 2, (supplementary table) ).
In the context of infectious diseases of the CNS, we could not find any studies reporting the influence of intracranial hypertension in the concentrations of antifungal or antibacterial agents in the CNS after a systematic search on the MEDLINE. Our results have shown that variations of intracranial pressure did influence AmB and FCZ levels in the CSF. Our data suggest that dose modifications of antifungal agents including AmB and FCZ are not necessary for patients with cryptococcal meningitis and intracranial hypertension. The limitations of our study include the small number of patients evaluated and the fact that we could not assess 5´flucytosine, which is an important antifungal agent for treating patients with cryptococcal meningitis. Additional studies addressing the role of intracranial hypertension on pharmacodynamic and pharmacokinetics of novel antifungal agents in patients with cryptococcal meningitis are necessary.
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